Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.
about
Promising new treatments for psoriasisImmunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesCholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragmentsComparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort studyPredictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing SpondylitisImmunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center CohortInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic InflammationSynthetic antibodies as therapeutics.Histoplasma capsulatum proteome response to decreased iron availabilityA white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional studyMolecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapiesType 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritisOutcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis.Immunogenicity to biologics: mechanisms, prediction and reduction.Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma.TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammationInfluence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.Original inhibition method of excessive synthesis of pro-inflammatory cytokine of tumour necrosis factor α.Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.Current imaging strategies in rheumatoid arthritisTumor necrosis factor-alpha antagonism by the murine tumor necrosis factor-alpha receptor 2-Fc fusion protein exacerbates histoplasmosis in miceAdalimumab therapy for recalcitrant pyoderma gangrenosum.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesTNF-alpha antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis.Review and clinical perspectives for the use of infliximab in ulcerative colitis.Adalimumab in Crohn's diseaseDrug focus: adalimumab in the treatment of moderate to severe psoriasis.Adalimumab for the treatment of Crohn's disease.Acute infusion reactions induced by monoclonal antibody therapy.The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment responseImmunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?Assays for Infliximab Drug Levels and Antibodies: A Matter of Scales and Categories.
P2860
Q24598008-946E4394-28D3-48E5-9828-C57C0ABCE9F4Q26766424-4670564F-EC1B-400B-9284-6E6E4E0849D8Q28535018-87CD510B-EC18-4145-A226-E42DF0C05D53Q28542423-2BD0C5E0-76FA-4B05-8855-9E4479162BFAQ28546596-40A9F308-11A2-432E-A884-135B25287412Q28554222-85ADB8BA-8272-421E-B08E-BE1666262951Q30240229-F16D4E19-0761-47DF-A7E8-2376C4A40814Q30412650-904521B9-3F9F-4913-9CB3-701C07EBD0DEQ31122092-A27EE9DE-8745-4E77-B898-12E88E0B4EC0Q33265617-24C9FC85-2B40-4514-9B00-DEE08270F842Q33395856-0221CC78-22A9-4FCE-9A61-AE309CC45B81Q33574171-D8A5E329-AD23-44E5-9A22-244B7CA270FFQ33610284-3BB260E7-A7F1-4F62-9540-DB8B95D4E823Q33629320-A0485AC8-ED8F-4D3D-8965-0E6839DEF07EQ33822653-13260D5B-312B-49EE-9A01-0CA3B708E9BCQ33924120-328B8F0C-F238-4D2B-A3EE-11C144C68A1FQ34153033-7BE5B4BD-A8AD-4CE3-BFB2-43DA55B10668Q34296526-661AAADB-F435-4B9A-A0D5-025E2B1F4D52Q34413235-91A3943A-4E1C-4980-BCFF-25599E078BB0Q35537338-39320FD5-5568-4624-A508-F97693024E95Q35540023-A590D615-FF7E-4C88-98AA-8D1F8A92C560Q35592110-0EFE48C1-A1F5-4B96-BB9D-1CC6063538B1Q35999197-B75951CE-3723-423C-A6AF-9747C32E114BQ36305630-CEE1DEB8-2080-4EEE-B491-32B0827736C8Q36331865-C3EF10DB-859B-4B4F-89AF-15C954DE36A9Q36337258-EA93F400-63F5-4947-BB66-0D18F9A5BC79Q36400358-D309F9E7-DC5B-41D8-AD8E-7EFCEFF5342BQ36675139-4AA1DB8F-A740-481C-8BBA-AC14BD19BE1CQ36724093-DD8203F2-EDEE-44BC-A822-64A6147A476DQ36749486-53758754-1D0A-40B4-A3CA-6C4782B135D8Q37114650-79905392-FA67-4AD9-ADF2-AEF36E7C0C46Q37290464-051786A4-00AB-48BD-B710-FD41D9F09697Q37290478-D65BEDA5-3591-414F-AE02-081941CA81E7Q37307855-697742E9-3764-483B-A382-90E991D87BCFQ37821495-296239F4-C533-4AF7-A748-F2C21E57A147Q38033127-22B9474D-2A52-48A5-BBF8-7FC1248E8F08Q38045471-D48B0BA1-3077-4FF5-A703-466B648D67CDQ38118313-51941A1A-5B3A-4291-A06D-0ED041EA4F4FQ38150903-D3B57A3D-500E-46C6-86A9-27AF721141A7Q38754643-AD737653-21F3-4D73-8072-EDEECA22B4C3
P2860
Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@ast
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@en
type
label
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@ast
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@en
prefLabel
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@ast
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@en
P1476
Tumor necrosis factor inhibito ...... erent immunogenicity profiles.
@en
P2093
Paul J Anderson
P356
10.1016/J.SEMARTHRIT.2005.01.005
P433
P577
2005-04-01T00:00:00Z